Journal: Lipids

Article Title: Antibacterial activity of hexadecynoic acid isomers towards clinical isolates of multidrug-resistant Staphylococcus aureus

doi: 10.1002/lipd.12213

Figure Lengend Snippet: Antibacterial activity of HDA analogs against multidrug-resistant bacteria. a

Article Snippet: It was also observed that 3-HDA is 32- to 255-fold less active than 1 in all S. aureus strains displayed in . table ft1 table-wrap mode="anchored" t5 Table 2. caption a7 Compounds MIC/GI 50 ± SEM, μg/mL Bacterial Strains S. aureus ATCC 29213 b CIMRSA XI CIMRSA XII CIMRSA XIII CIMRSA XIV CIMRSA XV CIMRSA XVI E. coli ATCC 25922 b 1 7.8/ 3.3 ± 0.3 0.49/0.30 ± 0.03 0.49/0.25 ± 0.03 0.24/0.16 ± 0.02 0.49/0.34 ± 0.03 0.49/0.27 ± 0.01 0.49/0.30 ± 0.03 >1,00 3-HDA ( 7a ) 250/107.8± 5.4 62.5/43.4 ± 1.1 125/89.2 ± 0.9 500/200.6 ± 1.1 62.5/35.1 ± 3.5 15.6/8.7 ± 0.9 62.5/37.9 ± 3.8 >1,000 Open in a separate window a Experiments were performed in triplicate (N =3).

Techniques: Activity Assay, Bacteria

Journal: Lipids

Article Title: Antibacterial activity of hexadecynoic acid isomers towards clinical isolates of multidrug-resistant Staphylococcus aureus

doi: 10.1002/lipd.12213

Figure Lengend Snippet: Comparison of the antibacterial activities of both 3-HDA and 1 in six CIMRSA strains a

Article Snippet: It was also observed that 3-HDA is 32- to 255-fold less active than 1 in all S. aureus strains displayed in . table ft1 table-wrap mode="anchored" t5 Table 2. caption a7 Compounds MIC/GI 50 ± SEM, μg/mL Bacterial Strains S. aureus ATCC 29213 b CIMRSA XI CIMRSA XII CIMRSA XIII CIMRSA XIV CIMRSA XV CIMRSA XVI E. coli ATCC 25922 b 1 7.8/ 3.3 ± 0.3 0.49/0.30 ± 0.03 0.49/0.25 ± 0.03 0.24/0.16 ± 0.02 0.49/0.34 ± 0.03 0.49/0.27 ± 0.01 0.49/0.30 ± 0.03 >1,00 3-HDA ( 7a ) 250/107.8± 5.4 62.5/43.4 ± 1.1 125/89.2 ± 0.9 500/200.6 ± 1.1 62.5/35.1 ± 3.5 15.6/8.7 ± 0.9 62.5/37.9 ± 3.8 >1,000 Open in a separate window a Experiments were performed in triplicate (N =3).

Techniques: Comparison

Journal: Lipids

Article Title: Antibacterial activity of hexadecynoic acid isomers towards clinical isolates of multidrug-resistant Staphylococcus aureus

doi: 10.1002/lipd.12213

Figure Lengend Snippet: CIMRSA XIII growth curve showing its log-phase in TSB when treated with 1 (960 ng/mL), Cipro (250 μg/mL), and palmitic acid (4 mg/mL). CIMRSA XIII treated with 1% DMSO was used as control. Experiments were performed in three biological replicates (N =3).

Article Snippet: It was also observed that 3-HDA is 32- to 255-fold less active than 1 in all S. aureus strains displayed in . table ft1 table-wrap mode="anchored" t5 Table 2. caption a7 Compounds MIC/GI 50 ± SEM, μg/mL Bacterial Strains S. aureus ATCC 29213 b CIMRSA XI CIMRSA XII CIMRSA XIII CIMRSA XIV CIMRSA XV CIMRSA XVI E. coli ATCC 25922 b 1 7.8/ 3.3 ± 0.3 0.49/0.30 ± 0.03 0.49/0.25 ± 0.03 0.24/0.16 ± 0.02 0.49/0.34 ± 0.03 0.49/0.27 ± 0.01 0.49/0.30 ± 0.03 >1,00 3-HDA ( 7a ) 250/107.8± 5.4 62.5/43.4 ± 1.1 125/89.2 ± 0.9 500/200.6 ± 1.1 62.5/35.1 ± 3.5 15.6/8.7 ± 0.9 62.5/37.9 ± 3.8 >1,000 Open in a separate window a Experiments were performed in triplicate (N =3).

Techniques: Control

Journal: Lipids

Article Title: Antibacterial activity of hexadecynoic acid isomers towards clinical isolates of multidrug-resistant Staphylococcus aureus

doi: 10.1002/lipd.12213

Figure Lengend Snippet: A) FA profiles of both non-treated and 1-treated CIMRSA XIII. CIMRSA XIII cells were grown at 37 °C for 18–20 h in TSB containing 0.16 μg/mL 1 (treated), or in its absence (untreated). FA were eluted, converted to methyl-esters and analyzed by GC-MS, as described in materials and methods. Bars represent the percentage of different FAs obtained from three separated experiments (mean ± SD). FA nomenclature indicates the type of branched FA, the number of carbons followed by the number of double bonds. Acid 1 refers to 2-hexadecynoic acid. B) Comparison of iso-, anteiso-, and straight-FA acids that are present in 1-treated- and non-treated-CIMRSA XIII. Histograms were constructed by classifying all branched FA and non-branched FA from three independent experiments (mean ± SD) that were previously identified based on their molecular ion, base peak, fragmentation pattern, retention time, and ECL values. Multiple t test analyses were performed using GraphPad Prism® v.6.01 and revealed statistical difference between iso-FA and anteiso-FA, since p = 0.0422 (*) and p = 0.0031 (**) were obtained.

Article Snippet: It was also observed that 3-HDA is 32- to 255-fold less active than 1 in all S. aureus strains displayed in . table ft1 table-wrap mode="anchored" t5 Table 2. caption a7 Compounds MIC/GI 50 ± SEM, μg/mL Bacterial Strains S. aureus ATCC 29213 b CIMRSA XI CIMRSA XII CIMRSA XIII CIMRSA XIV CIMRSA XV CIMRSA XVI E. coli ATCC 25922 b 1 7.8/ 3.3 ± 0.3 0.49/0.30 ± 0.03 0.49/0.25 ± 0.03 0.24/0.16 ± 0.02 0.49/0.34 ± 0.03 0.49/0.27 ± 0.01 0.49/0.30 ± 0.03 >1,00 3-HDA ( 7a ) 250/107.8± 5.4 62.5/43.4 ± 1.1 125/89.2 ± 0.9 500/200.6 ± 1.1 62.5/35.1 ± 3.5 15.6/8.7 ± 0.9 62.5/37.9 ± 3.8 >1,000 Open in a separate window a Experiments were performed in triplicate (N =3).

Techniques: Gas Chromatography-Mass Spectrometry, Comparison, Construct

Journal: Lipids

Article Title: Antibacterial activity of hexadecynoic acid isomers towards clinical isolates of multidrug-resistant Staphylococcus aureus

doi: 10.1002/lipd.12213

Figure Lengend Snippet: GAPDH specific activity from lysates of CIMRSA XIII without treatment (control), CIMRSA XIII treated with 1% DMSO, and CIMRSA treated with 0.16 μg/mL of 1. Experiments were performed in three biological replicates (N =3). One-way ANOVA followed by Dunnett’s test were performed using GraphPad Prism V. 6.01. Non-statistical differences between mean values were obtained since p values higher than 0.05 were obtained. 2-HDA = 1.

Article Snippet: It was also observed that 3-HDA is 32- to 255-fold less active than 1 in all S. aureus strains displayed in . table ft1 table-wrap mode="anchored" t5 Table 2. caption a7 Compounds MIC/GI 50 ± SEM, μg/mL Bacterial Strains S. aureus ATCC 29213 b CIMRSA XI CIMRSA XII CIMRSA XIII CIMRSA XIV CIMRSA XV CIMRSA XVI E. coli ATCC 25922 b 1 7.8/ 3.3 ± 0.3 0.49/0.30 ± 0.03 0.49/0.25 ± 0.03 0.24/0.16 ± 0.02 0.49/0.34 ± 0.03 0.49/0.27 ± 0.01 0.49/0.30 ± 0.03 >1,00 3-HDA ( 7a ) 250/107.8± 5.4 62.5/43.4 ± 1.1 125/89.2 ± 0.9 500/200.6 ± 1.1 62.5/35.1 ± 3.5 15.6/8.7 ± 0.9 62.5/37.9 ± 3.8 >1,000 Open in a separate window a Experiments were performed in triplicate (N =3).

Techniques: Activity Assay, Control